Form 4: PAVmed CEO Aklog Granted 150,000 Restricted Shares

PAVmed Inc.'s Chairman and CEO, Lishan Aklog, was granted 150,000 restricted shares of common stock, vesting in May 2028.

Summary

• Lishan Aklog, Chairman and CEO of PAVmed Inc., received a grant of 150,000 restricted shares of common stock.
• The grant occurred on September 30, 2025, with a single vesting date of May 20, 2028.
• These shares are subject to forfeiture if the requisite service period is not completed.
• The grant was made under the issuer's Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan and is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• Following this transaction, Aklog directly owns 228,418 shares and indirectly controls an additional 298,590 shares through family members and investment entities.

Sentiment

Score: 7

Explanation: The grant of restricted stock to the CEO is a positive signal for long-term alignment of management and shareholder interests, indicating confidence and a commitment to the company's future. However, it's a compensation event, not a direct cash investment by the insider.

Positives

• Demonstrates long-term commitment and alignment of the CEO's interests with shareholders through a significant restricted stock grant.
• The grant is part of a long-term incentive plan, suggesting a strategic approach to executive compensation and retention.
• Increases the CEO's direct beneficial ownership, signaling confidence in the company's future trajectory.

Negatives

• The restricted shares are subject to forfeiture, meaning the CEO must remain with the company until May 20, 2028, to fully realize the value.
• The grant does not represent an open market purchase, which would typically signal a direct cash investment by the insider.
• The shares have a zero acquisition price, indicating they are compensation rather than a personal investment of capital.

Risks

• Forfeiture Risk: The restricted stock is subject to forfeiture if the CEO does not complete the requisite service period until May 20, 2028.
• Market Value Risk: The ultimate value of the granted shares depends on PAVmed Inc.'s stock price performance until and after the vesting date.
• Dilution Risk: While not directly stated as a risk in the filing, future equity grants can contribute to share dilution over time.

Future Outlook

The grant of restricted stock with a future vesting date of May 20, 2028, indicates a long-term incentive structure designed to retain the CEO and align his interests with the company's long-term performance and strategic objectives.

Management Comments

• The restricted stock grant to Chairman and CEO Lishan Aklog was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer, intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). This aligns management's interests with shareholder value over the long term.

Industry Context

Restricted stock grants are a common form of executive compensation in publicly traded companies, particularly in the healthcare and technology sectors, aiming to incentivize long-term performance and retention. This practice aligns with broader industry trends of linking executive pay to future company success and is a standard component of executive compensation packages.

Comparison to Industry Standards

• Restricted stock awards are a standard component of executive compensation packages across various industries, including biotech and medical devices, similar to grants observed at comparable companies for their executives.
• The vesting schedule, a single cliff vest in 2028, is a common structure for long-term retention, though multi-year graded vesting is also prevalent in the industry.
• The size of the grant, 150,000 shares, would need to be evaluated against PAVmed's market capitalization and peer group compensation data to determine if it is within typical industry ranges for a CEO of a company of its size and stage.

Related Party Transactions

• Lishan Aklog has indirect beneficial ownership of 297,105 shares through Pavilion Venture Partners LLC, where he is the sole manager.
• Lishan Aklog has indirect beneficial ownership of 1,333 shares through HCFP/AG LLC, where he is a co-manager.
• Lishan Aklog also has indirect beneficial ownership of 154 shares by his daughter and 152 shares by his son.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of CEO's interests with long-term shareholder value; however, future dilution from equity grants is a consideration.
• Employees: May set a precedent for executive compensation structures and long-term incentive plans within the company.

Next Steps

• Completion of the requisite service period by Lishan Aklog for the restricted shares to vest on May 20, 2028.

Key Dates

Recommendation

The restricted stock grant to the CEO is a positive indicator of long-term commitment and alignment of interests, which can be viewed favorably by investors. However, it is a compensation event rather than a direct cash investment, and while generally positive, it does not fundamentally alter the company's financial position or operational outlook to warrant a 'buy' or 'sell' recommendation based solely on this filing. It reinforces a 'hold' position for investors already confident in the company's long-term strategy.

Keywords

PAVmed Inc., PAVM, Lishan Aklog, Restricted Stock, CEO Compensation, Insider Ownership, SEC Form 4, Equity Grant, Long-Term Incentive